Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Endocrinology
Study Phase : Phase II
Recipient : State University of New York at Buffalo
Deal Size : Inapplicable
Deal Type : Inapplicable
Impact of Periodontal Therapy on Patients With Diabetes
Details : Chlorhexidine Gluconate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 05, 2021
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Recipient : State University of New York at Buffalo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : L. Reuteri
Therapeutic Area : Dental and Oral Health
Study Phase : Undisclosed
Recipient : University Hospital, Lille
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Probiotics on the Periodontal Status of Orthodontic Patients
Details : L. Reuteri is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Gingivitis.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
November 18, 2020
Lead Product(s) : L. Reuteri
Therapeutic Area : Dental and Oral Health
Highest Development Status : Undisclosed
Recipient : University Hospital, Lille
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
